Henlius Bevacizumab Trials Results Get International Recognition
As Company Submits HLX04 For Approval In China
Executive Summary
China’s Henlius has received international recognition of Phase I and III clinical trial results for its bevacizumab biosimilar, HLX04, providing “strong evidence for the efficacy and safety similarity between HLX04 and the reference bevacizumab.” The company has submitted its NDA for the product to the NMPA for various indications.
You may also be interested in...
Henlius Doses First Patient In China For Ophthalmic Bevacizumab
Chinese firms Shanghai Henlius Biotech and Essex Bio-Technology have announced a key milestone in their Chinese Phase I clinical study for the HLX04-O biosimilar bevacizumab candidate to treat wet age-related macular degeneration.
Henlius’ Rituximab Results Bolster RA Ambitions In China
Shanghai Henlius Biotech has taken its groundbreaking Chinese rituximab biosimilar a step closer to securing a key rheumatoid arthritis indication.
Henlius’ Ophthalmic Bevacizumab Program Moves Ahead
Shanghai Henlius Biotech is planning to move forward with wet AMD trials for its bevacizumab biosimilar rival to Avastin following a nod from the US FDA.